Haleon plc: 2025 Half Year Results
31 July 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces its half year results statement for the year ending 31 December 2025 is available at http://www.rns-pdf.londonstockexchange.com/rns/2714T_1-2025-7-30.pdf.
The half year results statement will also be available on the Haleon website www.haleon.com/investors , and the results have been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
Dividend
Consistent with our policy to pay approximately one third of the prior year full year dividend as the interim dividend the Board has declared a H1 2025 interim dividend of 2.2 pence per ordinary share, up 10% on the interim dividend in 2024. This interim dividend is expected to be paid on 18 September 2025 to holders of ordinary shares and US American Depositary Shares (ADS) on the register as of 15 August 2025 (the record date). The ex-dividend date is expected to be 14 August 2025 for ordinary shareholders and 15 August 2025 for holders of ADS. For ordinary shareholders wishing to participate in the Dividend Reinvestment Programme (DRIP), the election deadline for the DRIP is 1 September 2025. The DRIP is provided by Equiniti Financial Services Limited, more information is available at www.shareview.co.uk/info/drip .
Subject to market conditions and Board approval, Haleon expects to grow its ordinary dividend at least in line with adjusted earnings.
Presentation for analysts and shareholders
A recorded results presentation by Brian McNamara, Chief Executive Officer, and Dawn Allen, Chief Financial Officer, will be available shortly after 7:00am BST (8:00 am CEST) on 31 July 2025 and can be accessed at www.haleon.com/investors. This will be followed by a Q&A session at 9:30am BST (10:30am CEST).
For analysts and shareholders wishing to ask questions, please use the dial-in details below which will have a Q&A facility:
| UK: |
+44 (0) 808 189 0158 |
| US: |
+1 855 979 6654 |
| All other: |
+44 (0) 203 936 2999 |
| Passcode: |
656863 |
An archived webcast of the presentation will be available later on the day of the results and can be accessed at www.haleon.com/investors .
This information contains regulated information as per 6.3.7R of the Disclosure and Transparency Rules of the Financial Conduct Authority.
Amanda Mellor
Company Secretary
Enquiries
|
Investors |
Media
|
||
| Jo Russell |
+44 7787 392441 |
Zoë Bird |
+44 7736 746167 |
| Rakesh Patel |
+44 7552 484646 |
Victoria Durman |
+44 7894 505730 |
|
Email: investor-relations@haleon.com |
Email: corporate.media@haleon.com |
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information please visit www.haleon.com .
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.